
- /
- Supported exchanges
- / F
PHARVARIS N.V. EO -12 (9EN F) stock market data APIs
PHARVARIS N.V. EO -12 Financial Data Overview
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get PHARVARIS N.V. EO -12 data using free add-ons & libraries
Get PHARVARIS N.V. EO -12 Fundamental Data
PHARVARIS N.V. EO -12 Fundamental data includes:
- Net Revenue: 0
- EBITDA: -116 103 928
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: -0.5
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
PHARVARIS N.V. EO -12 News

Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
Pharvaris N.V. ZUG, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent h...


Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
Pharvaris N.V. Antagonism of the bradykinin B2 receptor via treatment with deucrictibant resulted in statistically significant reduction in rate of HAE attacks ZUG, Switzerland, Feb. 22, 2024 (GLOBE...

Pharvaris Announces Extraordinary Meeting of Shareholders
Pharvaris N.V. ZUG, Switzerland , Feb. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent h...

Pharvaris to Present at the WSAAI Annual Meeting 2024
Pharvaris N.V. ZUG, Switzerland, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent he...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.